We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,300

Open access books available

172,000

International authors and editors

190M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Anti-Glomerular Basement Membrane Disease

Kouichi Hirayama and Kunihiro Yamagata
*Tokyo Medical University Ibaraki Medical Center,
 University of Tsukuba
 Japan*

1. Introduction

Anti-glomerular basement membrane (anti-GBM) disease is a rare autoimmune disorder characterized by rapidly progressive glomerulonephritis (RPGN) with diffuse crescentic formation on renal biopsy, and it is a well-characterized cause of glomerulonephritis.

In 1919, an autopsy of an 18-year-old male patient, who had developed hemoptysis and acute renal failure after experiencing flu-like symptoms, revealed massive alveolar hemorrhage, glomerulonephritis with fibrinous exudates in Bowman's capsule and necrotizing vasculitis in the spleen and gut (Goodpasture, 1919). Stanton and Tange reported 9 cases with alveolar hemorrhage and RPGN as Goodpasture's syndrome (Stanton & Tange, 1958). Anti-GBM disease was defined as the presence of serum autoantibodies to the noncollagenous domain of the alpha 3 chain of type IV collagen or a linear binding of IgG to glomerular capillary walls as detected by direct immunofluorescence in patients with RPGN. Anti-GBM disease was divided into two types: anti-GBM disease without alveolar hemorrhage was regarded as renal-limited anti-GBM disease, and that with alveolar hemorrhage was defined as Goodpasture's syndrome.

This review focuses on anti-GBM disease by comparing international differences in prevalence, clinical features, treatments and outcomes in order to improve the prognosis of anti-GBM disease.

2. Prevalence

Anti-GBM disease is relatively rare, with an estimated annual incidence of about 0.5-1.0/million population (Table 1). It has been estimated to cause 0.2-2.4% of biopsy-proven glomerulonephritis cases in Europe, but less than 0.2% in Asia. It causes about 10% of RPGN (or necrotizing and/or crescentic glomerulonephritis) in Europe, more than 10% of RPGN in the United States, and less than 10% in Asia. In Japan, to improve the prognosis of patients with RPGN, a nation-wide survey of patients with RPGN in 365 hospitals between 1989 and 2000 was conducted, and clinical characteristics including initial symptoms, laboratory findings and histological findings were investigated along with treatment methods and outcomes (Hirayama et al., 2008). Among patients with RPGN, 6.6% had anti-GBM disease. In comparison with foreign countries, this Japanese rate of anti-GBM disease in RPGN was lower.

Authors	Year	Nation	Incidence (/million/yr)	Frequency (%)		
				GN	2 nd GN	RPGN
Rychlík et al.	2004	Czech	0.17	0.31 *	1.2 *	
Heaf et al.	1999	Denmark	0.6			12.8 +
Andrassy et al.	1991	Germany	0.55			7.9
Daly et al.	1996	Ireland		2.4 *		
Schena et al.	1997	Italy	0.1	0.20 *	1.5 *	
Grcevska et al.	1995	Macedonia				3.6 +
Naumovic et al.	2009	Serbia	0.02	0.18 *	0.74 *	
Rivera et al.	2002	Spain				14.6 +
Saxena et al.	1991	Sweden				13.4 +
Williams et al.	1988	United Kingdom	1.12(0.2 – 4.0)			
Angangco et al.	1994	United Kingdom		0.81 *		11.2 +
Parfrey et al.	1985	Canada				11.5 +
Wilson and Dixon	1973	United States		7.0 *		
Jennette	1993	United States				14.6 +
Briganti et al.	2001	Australia	0.99	0.8 *		
NZGS	1989	New Zealand		5.9 *		
Date et al.	1987	India		0.04 *		
Sumethkul et al.	1999	Thai		0.10 *		3.3 +
Tang et al.	2003	China		0.15 *		8.7 +
Li, FK. et al.	2004	China(HongKong)	0.6			
Li, LS. et al.	2004	China		0.21 *	0.86 *	
Hirayama et al.	2008	Japan				6.6

The incidence of patients with anti-GBM disease is expressed as the number per 1 million population per year. The frequencies of patients with anti-GBM disease in glomerulonephritis, secondary glomerulonephritis or rapidly progressive glomerulonephritis are expressed as percentages. *Biopsy-proven glomerulonephritis. Blanks are unavailable data. Abbreviations: yr, years; GN, glomerulonephritis; 2nd GN, secondary glomerulonephritis; RPGN, rapidly progressive glomerulonephritis (including *necrotizing and/or crescentic glomerulonephritis); NZGS, The New Zealand Glomerulonephritis Study.

Table 1. Prevalence of anti-GBM disease in various countries.

All age groups are affected, but the peak incidence of anti-GBM disease is in the third decade in young men, with a second peak in the sixth and seventh decades affecting men and women equally (Figure 1). Alveolar hemorrhage is more common in younger men, while isolated renal disease is more frequent in the elderly, with a near-equal gender distribution. In that survey (Hirayama et al., 2008), the mean age at onset of renal-limited anti-GBM disease was 52.6±17.0 years. There was only one peak incidence of anti-GBM disease, and this peak occurred in the fifth and sixth decades. The gender distribution was nearly equal in renal-limited anti-GBM disease (male: female = 1: 0.94).

Fig. 1. Investigations of age distribution in anti-GBM disease (upper) and Goodpasture's syndrome (lower).

The histograms show the number of patients with anti-GBM disease classified by patient age at the onset of the disease. Abbreviations: GN, glomerulonephritis; Biopsy, biopsy-proven glomerulonephritis; RPGN, rapidly progressive glomerulonephritis; NZGS, The New Zealand Glomerulonephritis Study; N.A., not available.

Alveolar hemorrhage is observed in 35-62% of patients with anti-GBM disease in Europe, the United States, and China, and it is more common in younger patients and in men, whereas renal-limited anti-GBM disease is more common in older patients and in women. In Japan, alveolar hemorrhage of patients with anti-GBM disease was less frequent (23.4%) and the age at onset of Goodpasture's syndrome was lower (49.4 ± 14.4 years), but it was more common in females (male: female = 1: 1.75).

This disease appears to be more common in Caucasians and very rare in those of African origin (Pusey, 2003; Ooi et al., 2008). There is apparently a higher incidence of onset of Goodpasture's disease in the spring and summer, as well as localized clustering of the disease, perhaps suggesting an infectious relationship (Pusey, 2003). Anecdotal associations with urinary tract infections and lithotripsy, which may subclinically affect the glomerular basement membrane, have also been reported (Pusey, 2003; Ooi et al., 2008).

3. Pathogenesis

In 1934, Masugi reported nephrotoxic glomerulonephritis induced by anti-kidney serum in an experimental model (Masugi, 1934), after which a linear binding of IgG to glomerular capillary walls was detected by direct immunofluorescence (Ortega & Mellors, 1956). In 1964, a linear immunostaining of IgG was observed in 2 patients with Goodpasture's syndrome (Scheer & Grossman, 1964), and in another study the kidney serum of patients with Goodpasture's syndrome and of patients with crescentic glomerulonephritis without alveolar hemorrhage contained antibodies that reacted with the GBM of humans and animals (Lerner et al., 1967). Those authors also demonstrated that those anti-GBM antibodies caused glomerulonephritis when injected into animals.

3.1 Structure of GBM

GBM, which exists between endothelial cells and podocytes, consists of type IV collagen, heparansulphate proteoglycan, laminine and fibronectin. Type IV collagen, which consists of 3 of 6 alpha-chains ($\alpha 1$ to $\alpha 6$) encoded by three pairs of genes on chromosomes 2, 13 and X, and its molecules were trimeric ($\alpha 1\alpha 1\alpha 2$, $\alpha 3\alpha 4\alpha 5$ and $\alpha 5\alpha 5\alpha 6$). This basement membrane, found in kidney, lung, cochlea and eye, comprises the surface on which epithelial cells rest. In kidneys, $\alpha 3\alpha 4\alpha 5$ molecules were found in the GBM, particularly the epithelial side; $\alpha 1\alpha 1\alpha 2$ molecules were in the mesangium, the endothelial side of the GBM, tubular basement membranes and Bowman's capsule; and $\alpha 5\alpha 5\alpha 6$ molecules were in tubular basement membranes and Bowman's capsule. Each alpha-chain was made by one long collagenous domain and two terminal noncollagenous globular domains: the C-terminal noncollagenous (NC1) domain and the N-terminal domain (the 7S domain). Mature GBM is a lattice-like structure comprised in part by heterotrimers of $\alpha 3$, 4 and 5 chains, which form a triple helix with short NC1 and 7S domains (Sado et al., 1998). The NC1 domain of the $\alpha 3$ chain of a tissue-specific type IV collagen [$\alpha 3(\text{IV})\text{NC1}$] monomer is structured into the collagen IV network through the association of $\alpha 3$, $\alpha 4$ and $\alpha 5$ chains to form a triple helical protomer and through the oligomerization of these protomers via end-to-end associations and intertwining of triple helixes (Hudson et al., 2003).

3.2 Anti-GBM antibodies

The target of the anti-GBM antibodies was identified as $\alpha 3(\text{IV})\text{NC1}$ (Saus et al., 1988). The two conformational epitopes of anti-GBM antibodies have been defined as E_A and E_B

(Kalluri et al., 1996; Borza et al., 2000). The E_A epitope is 17-31 amino acids on the N-terminal side, and the E_B epitope is 127-141 amino acids on the C-terminal side (Netzer et al., 1999). Alterations of the amino acid sequence translated by the COL4A3 gene, which encodes $\alpha 3(\text{IV})\text{NC1}$, are not major factors, because no mutation of the COL4A3 gene was found (Persson et al., 2004). It was suggested that E_A and E_B, as cryptic B-cell epitopes, were enclosed in the quaternary structure of the hexamers created by sulfilimine crosslinks between the trimers of adjacent NC1 chains (Vanacore et al., 2008, 2009). Recently, in patients with Goodpasture's disease, elevated autoantibody titers to $\alpha 3(\text{IV})\text{NC1}$ and $\alpha 5(\text{IV})\text{NC1}$ monomers at diagnosis were associated with the eventual loss of renal function (Pedchenko et al., 2010). In that study, these anti-GBM antibodies bound to specific epitopes that encompassed region E_A in the $\alpha 5(\text{IV})\text{NC1}$ monomer and regions E_A and E_B in the $\alpha 3(\text{IV})\text{NC1}$ monomer, but did not bind to the native crosslinked $\alpha 345(\text{IV})\text{NC1}$ hexamer. Thus, it is a dissociation of the NC1 hexamers that expose the pathogenic epitopes on the $\alpha 3$ and $\alpha 5$ chains, precipitating the production of anti-GBM antibodies (Pedchenko et al., 2010). It was suggested that the autoantibody itself may subsequently alter antigen conformation and expose further epitopes, causing an epitope-spreading phenomenon (Salant, 2010).

3.3 Crescent formations

The anti-GBM antibody bound to GBM ligates Fc receptors, leading to the activation of monocytes, neutrophils, eosinophils, basophils and macrophages. These release chemokines that attract a further influx of neutrophils into glomeruli, causing severe tissue injury, including the disruption of the GBM. Renal injury in anti-GBM disease is amplified by the activation of complements and protease after the binding (Sheerin et al., 1997; Baricos et al., 1991). The release of reactive oxygen species by neutrophils is also probably an important pathogenic mechanism of tissue injury.

The histogenesis and origin of cellular crescents, which are cap-like multilayered accumulations of proliferating cells, have remained controversial. Although early ultrastructural studies suggested that crescents are formed by proliferating epithelial cells (Morita et al., 1973; Min et al., 1974), subsequent histochemical studies with antibodies against leukocytes identified the presence of monocytes-macrophages in cellular crescents (Atkins et al., 1976; Thomson et al., 1979). It was demonstrated that epithelial cells predominated in crescents of patients during the early phases of disease; later phases were characterized by rupture of the basement membrane of Bowman's capsule and subsequent infiltration of cellular crescents, predominantly by macrophages (Boucher et al., 1987). The composition of cellular crescents may change during the progression of disease after the inciting glomerular injury (Ophascharoensuk et al., 1998).

The main stimulus to the migration of macrophages and neutrophils is probably the exudation of fibrin in Bowman's space caused by the disruption of the GBM and Bowman's capsule (Tipping et al., 1988). Several possible causes of acute renal injury in anti-GBM disease were identified, including the functional roles of a number of macrophage proinflammatory mediators, such as IL-1 (Lan et al., 1993), TNF- α (Lan et al., 1997; Le Hir et al., 1998) and matrix metalloproteinase (Kaneko et al., 2003). In epithelial crescent formation in the glomerulus, thrombin generated by coagulation (He et al., 1991) and growth-factor cytokines (IL-1 and IL-2) released by monocytes and platelets (Adler et al., 1990) stimulate the migration of epithelial cells. Moreover, interleukin-12 (Kitching et al., 1999) and interferon- γ (Timoshanko et al., 2002) are also involved.

3.4 Environmental and genetic factors

Environmental factors are thought to play a role in triggering the disease. In the first case of Goodpasture's syndrome, intercurrent infection amplifies the intensity of inflammatory responses and can aggravate disease and so make it clinically apparent. There are a number of case reports of clusters of patients with anti-GBM disease (Perez et al., 1974), which may implicate an infective agent; however, no clear viral association has been identified. Group A type 12 streptococcal cell membrane shares some cross-reactivity with the human glomerular basement membrane, generating another hypothesis: that infection may initiate anti-GBM antibody production (Blue & Lange, 1975).

Goodpasture's syndrome has been noted to occur more frequently in smokers (Salama et al., 2001). Lazor et al. (2007) reported that 89% of their patients with Goodpasture's syndrome were active smokers. In another study, alveolar hemorrhage was present in 100% of patients who smoked and in only 20% of nonsmokers with Goodpasture's disease (Donaghy & Rees, 1983). No significant difference in circulating anti-GBM antibody titers was found between smokers and nonsmokers, suggesting that cigarette smoking may increase the permeability of lung capillaries and thus expose alveolar basement membranes to circulating anti-GBM antibodies (Donaghy & Rees, 1983; Klasa et al., 1988). Other inhaled substances may also be associated with anti-GBM disease, including cocaine (García-Rostan y Pérez et al., 1997; Lazor et al., 2007), hard metals such as inert tungsten carbide and cobalt (Lechleitner et al., 1993), smoke inhalation (Klasa et al., 1988) and possibly volatile hydrocarbon solvents (Beirne & Brennan, 1972; Bombassei & Kaplan, 1992). In particular, hydrocarbon exposure may influence the development of alveolar hemorrhage (Churchill et al., 1983; Bonzel et al., 1987). Another environmental factor, alemtuzumab, which is a humanized anti-CD52 monoclonal antibody, recently was identified as a cause of anti-GBM disease (Clatworthy et al., 2008).

Genetic factors appear to play a role in susceptibility to anti-GBM disease. As a genetic factor of anti-GBM disease, the human leukocyte antigen (HLA) complexes are known to influence susceptibility to anti-GBM disease. A strong association with HLA-DR2 specificity has been confirmed (Rees et al., 1978). In HLA genotyping, DRB1*1501 (the serologically defined HLA-DR2 gene) and DRB1*1502 (HLA-DR15 gene) allele at the DRB1 locus is associated with anti-GBM disease in Caucasians (Fisher et al., 1997), Chinese (Yang et al., 2009) and Japanese (Kitagawa et al., 2008). The strongest association was with HLA DRB1*1501 but, when the effect of this gene was excluded, subsequent analysis revealed an increased frequency of DRB1*04 and DRB1*03 and a decreased frequency of DRB1*07 and DRB1*01 (Phelps & Rees, 1999). Other genetic influences of anti-GBM disease have been identified, including the immunoglobulin heavy chain Gm locus that encodes the constant region of the IgG heavy chain (Rees et al., 1984), polymorphisms of FCGR genes that encode the Fc receptor for IgG (FcγR) (Zhou et al., 2010a, 2010b) and kallikrein genes (Liu et al., 2009).

4. Clinical symptoms

General malaise (fatigue), weight loss, fever, arthralgia or myalgia may be the initial features of anti-GBM disease in a pattern similar to but much less prominent than that in systemic vasculitis. Symptoms relating to anemia may also occur even in the absence of significant hemoptysis.

Authors	Year	Nation	symptoms					
			fatigue	fever	dys- pnea	hemo- ptysis	macro hemat- uria	oligo- anuria
Shah et al. *	2002	Various	15% (8/54)	28% (15/54)	26% (14/54)	65% (35/54)	7% (4/54)	17% (9/54)
Lazor et al.	2007	France & Switzerland	64% (18/28)	43% (12/28)	79% (22/28)	75% (21/28)	36% (10/28)	18% (5/28)
Merkel et al.	1994	Germany	40% (14/35)	28% (10/35)	14% (5/35)	51% (18/35)	20% (7/35)	N.A.
Daly et al.	1996	Ireland	N.A.	N.A.	N.A.	25% (10/40)	35% (14/40)	50% (20/40)
Williams et al.	1988	United Kingdom	N.A.	N.A.	10% (1/10)	10% (1/10)	10% (1/10)	60% (6/10)
Proskey et al. *	1970	United States	51% (29/56)	22% (12/56)	57% (32/56)	82% (46/56)	12% (7/56)	N.A.
Wilson et al.	1973	United States	34% (17/50)	14% (7/50)	32% (16/50)	46% (23/50)	42% (21/50)	10% (5/50)
Briggs et al.	1979	United States	22% (4/18)	11% (2/18)	44% (8/18)	50% (9/18)	56% (10/18)	N.A.
Walker et al.	1985	Australia	N.A.	N.A.	N.A.	62% (13/21)	N.A.	62% (13/21)
Teague et al. *	1978	New Zealand	68% (19/28)	26% (7/27)	78% (21/27)	86% (25/29)	43% (12/28)	N.A.
Li et al.	2004	China (Hong Kong)	N.A.	N.A.	N.A.	40% (4/10)	N.A.	40% (4/10)
Cui et al.	2005	China	N.A.	N.A.	N.A.	59% (57/97)	27% (26/97)	52% (50/97)
Hirayama et al.	2008	Japan	53% (25/47)	57% (27/47)	6% (3/47)	15% (7/47)	19% (9/47)	28% (13/47)

The frequencies of patients with each symptom are expressed as percentages. *All investigated patients had Goodpasture’s syndrome. Abbreviations: N.A., not available.

Table 2. Investigations of clinical symptoms in anti-GBM disease at the initial presentation.

The principal clinical features relate to the development of renal failure due to RPGN or alveolar hemorrhage (Table 2). Hemoptysis is the predominant symptom of alveolar hemorrhage. Alveolar hemorrhage may cause severe impairment of oxygenation, so intensive care and artificial ventilation are sometimes needed. The mild lung symptoms are only dry cough and shortness of breath. Although one-third to two-thirds of patients with anti-GBM disease demonstrate alveolar hemorrhage in general, in our survey, 23.4% (11/47) of patients with anti-GBM disease suffered from alveolar hemorrhage (Hirayama et al., 2008). A minority of patients exhibited macrohematuria. Anirua or oliguria was seen in 17-62% of patients at presentation, and these findings suggested a poorer prognosis (Levy et al., 2001; Hudson et al., 2003).

5. Laboratory examinations

In general, all patients with anti-GBM disease had microscopic hematuria on urinalysis. Proteinuria is modest, but can be heavier when the disease has a more subacute course. In our survey (Hirayama et al., 2008), the mean 24-hour excretion of urinary protein in renal-limited anti-GBM disease was 2.1±3.0 g and that of Goodpasture’s syndrome was 3.7±3.2 g.

Authors	Year	Nation	Urinary protein (g/day)	Serum creatinine (mg/dL)	ESRD (%)
Shah et al.	2002	Various	N.A.	6.62 (N.A.)	35% (27/78)
Herody et al.	1993	France	N.A.	N.A.	55% (16/29)
Lazor et al.	2007	France & Switzerland	1.2 (0 – 35.0)	1.27 (0.61 – 21.47)	41% (11/28)
Andrassy et al.	1991	Germany	6.4 (0 – 15.3)	12.8 (6.1 – 16.5)	67% (2/3)
Merkel et al.	1994	Germany	N.A. (0.2 – 3.5)	11.41 ± 5.64 (0.19 – 22.96)	71% (20/28)
Daly et al.	1996	Ireland	N.A.	5.1 ± 6.8 (N.A.)	50% (20/40)
Segelmark et al.	2003	Sweden	N.A.	8.94 (5.44 – 12.34)	46% (36/79)
Savage et al.	1986	United Kingdom	N.A.	N.A.	64% (69/108)
Williams et al.	1988	United Kingdom	N.A.	11.80 ± 4.67 (1.60 – 18.37)	70% (7/10)
Levy et al.	2001	United Kingdom	N.A.	3.59 (0.6 – 10.9)	55% (39/71)
Briggs et al.	1979	United States	2.6 ± 0.5 (1.9 – 3.5)	5.94 ± 7.11 (0.8 – 30.0)	33% (6/18)
Johnson et al.	1985	United States	4.3 ± 5.2 (0 – 22.0)	4.87 ± 6.93 (0.9 – 25.0)	12% (2/17)
Jennette	2003	United States	1.67 ± 3.35 (0.20– 16.20)	9.7 ± 7.2 (0.8 – 50)	N.A.
Walker et al.	1985	Australia	1.4 (0.4 – 5.4)	6.56 (1.24 – 32.35)	45% (10/22)
Simpson et al.	1982	New Zealand	N.A.	5.37 ± 5.22 (0.68 – 19.80)	10% (2/20)
Teague et al.	1978	New Zealand	N.A.	N.A.	14% (4/29)
Li et al.	2004	China (Hong Kong)	N.A.	6.96 ± 6.41 (1.19 – 22.09)	50% (5/10)
Cui et al.	2005	China	N.A.	N.A.	71% (69/97)
Hirayama et al	2008	Japan	2.4 ± 3.0 (0.1 – 12.2)	7.29 ± 4.19 (1.00 – 16.80)	60% (28/47)

Amounts of urinary protein and serum creatinine levels are expressed as means ± standard deviation or medians with ranges. Frequency of end-stage renal failure at presentation is expressed as a percentage. To convert serum creatinine in mg/dL to µmol/L, multiply by 88.4. Abbreviations: ESRD, end-stage renal disease; N.A., not available.

Table 3. Investigations of renal findings in anti-GBM disease at the initial presentation.

Unfortunately, most patients with anti-GBM disease had renal failure at the time of diagnosis, and the number of patients needing dialysis was not a few (Table 3). In our survey (Hirayama et al., 2008), the mean serum creatinine (s-Cr) level in renal-limited anti-GBM disease was 7.07±4.21 mg/dl, while that in Goodpasture’s syndrome was 7.99±4.31 mg/dl. Hemodialysis therapy had already been initiated in 59.6% (28/47) of the anti-GBM disease patients before the start of immunosuppressive treatments. Anemia was observed in most patients with anti-GBM disease, and the mean hemoglobin concentration in renal-limited anti-GBM disease was 8.8±1.7 g/dl, while that in Goodpasture’s syndrome was 7.5±1.1 g/dl. The mean erythrocyte sedimentation rate (ESR) in renal-limited anti-GBM disease was 105±44 mm/h, and that in Goodpasture’s syndrome

was 82 ± 45 mm/h. The mean serum C-reactive protein (CRP) level in renal-limited anti-GBM disease was 8.5 ± 7.2 mg/dl, and that in Goodpasture's syndrome was 8.2 ± 8.1 mg/dl. In comparison with other forms of RPGN, such as micropolyangiitis (MPA) and Wegener's granulomatosis (WG), there was no difference in inflammation markers such as leukocyte count, ESR and serum CRP. However, in patients with anti-GBM disease, the mean level of s-Cr at the time of diagnosis was higher than that in patients with MPA (4.54 ± 3.13 mg/dl) or WG (3.84 ± 3.24 mg/dl). Therefore, early diagnosis of anti-GBM disease is very important.

Although overt hemoptysis may not be immediately present in patients with Goodpasture's syndrome and alveolar hemorrhage may not be immediately obvious in radiological examinations, an elevated alveolo-arterial oxygen difference (AaPO₂) can be a sensitive indicator of alveolar hemorrhage. An elevated red blood cell count in bronchoalveolar lavages, as detected by bronchoscopy, is useful information for the diagnosis of alveolar hemorrhage, but lung biopsy does not contribute to this diagnosis (Lazor et al., 2007).

The diagnosis of anti-GBM disease is dependent on the detection of anti-GBM antibodies in either the circulation or the kidney tissue. These serum antibodies are usually detected using an enzyme-linked immunosorbent assay or radioimmunoassay method. The antibodies have not been reported to occur in the absence of disease, and false negatives are rare when appropriate checks are performed. In our survey (Hirayama et al., 2008), 91.5% (43/47) of patients with anti-GBM disease were diagnosed via the detection of serum anti-GBM antibodies.

In serological examinations, other autoantibodies were not usually detected. However, in our survey (Hirayama et al., 2008), anti-nuclear antibodies were detected in 11.8% of renal-limited anti-GBM disease and in 27.3% of patients with Goodpasture's syndrome. Anti-DNA antibody was not detected in renal-limited anti-GBM disease, but it was detected in 22.2% of patients with Goodpasture's syndrome. Moreover, anti-neutrophil cytoplasmic antibodies (ANCA) were detected in 12.8% (5/39) of patients with anti-GBM disease; a perinuclear pattern was detected in all five anti-GBM disease patients with ANCA, and a cytoplasmic pattern was detected in one. Anti-GBM antibody and ANCA coexisted in 15 - 50% of cases of anti-GBM disease described in the previous literature (Jayne et al., 1990; Bosch et al., 1991; Yang et al., 2005; Rutgers et al., 2005; Levy et al., 2004). Other studies revealed that patients with double-positive antibodies were predominantly MPO-ANCA, older and male (Jayne et al., 1990; Bosch et al., 1991; Yang et al., 2005; Rutgers et al., 2005). In our survey (Hirayama et al., 2008), the age at onset of patients with double-positive antibodies was higher (mean age, 52.6 years), but female-dominant (male : female = 1 : 4). The prognosis of patients with double-positive antibodies varied; the renal and patient survival rates of patients with double-positive antibodies were reported to be either better (Jayne et al., 1990; Bosch et al., 1991), not significantly different (Yang et al., 2005), or worse (Rutgers et al., 2005; Levy et al., 2004) than those of patients with anti-GBM antibody alone. In our survey (Hirayama et al., 2008), the prognosis of patients with double-positive antibodies was poor; two died and the remaining three required maintenance hemodialysis. Alveolar hemorrhage was observed in two of five patients with double-positive antibodies, and three of them had interstitial pneumonitis.

6. Imaging examinations

Kidneys were usually normal-sized or enlarged due to inflammation. In our survey (Hirayama et al., 2008), ultrasonography showed that 61.0% of patients with anti-GBM

disease had kidneys of normal size, while atrophic kidneys were observed in 12.2% of patients and enlarged kidneys were observed in 26.8%. There were no specific morphological abnormalities on any type of renal imaging examinations.

In cases with Goodpasture's syndrome, shadows usually involve the central lung fields with peripheral and upper-lobe sparing on chest radiography or computed tomography (Figure 2). Although the shadows are generally symmetrical, they can be markedly asymmetrical.

Fig. 2. Chest computed tomography in a patient with Goodpasture's syndrome.

Symmetrical shadows involved the central lung fields with peripheral sparing. Bilateral pleural effusions due to hypervolemia in acute kidney injury were also observed.

7. Pathological findings

A renal biopsy is essential in suspected anti-GBM disease both to confirm the diagnosis and to assess the renal prognosis. Glomerular fibrinoid necrosis and crescent formation with linear staining of the glomerular capillary walls for IgG are the histological hallmarks of anti-GBM disease.

7.1 Light microscopic findings

The histological pattern of disease starts with mesangial expansion and hypercellularity. It progresses to focal and segmental glomerulonephritis with infiltration by inflammatory cells, accompanied by segmental necrosis with prominent breaks in the GBM. Later, glomeruli develop an extensive crescent formation composed of parietal epithelial cells and macrophages in association with the destruction of the GBM (Figure 3). The crescents are usually at the same stage of evolution.

Fig. 3. Periodic acid-Schiff methenamine silver (PAM)-stained glomerulus in a patient with anti-GBM disease.

The disruption of the capillary walls, segmental necrosis and cellular crescent formation are observed. Rupture of the basement membrane of Bowman's capsule and periglomerular infiltration of inflammatory cells are also observed. Interstitial edema with infiltration of inflammatory cells is revealed.

Various degrees of crescent formation are observed in more than 90% of patients with anti-GBM disease. In Europe, the United States and Asian-Pacific, including Japan, the mean percentage of glomeruli showing crescent formation ranged from 40% to 100%, and about 70% to 100% of patients with anti-GBM disease had more than 50% crescentic glomeruli (Figure 4). Anti-GBM disease is pathologically the most severe form of glomerulonephritis (Holdsworth et al., 1985; Jennette, 2003, Hirayama et al., 2008).

Although tubules are usually normal, epithelial flattening is revealed in the severe acute phase. In the chronic phase, tubules in the area of severe injury undergo atrophy and some disappear. Acute tubulitis sometimes occurs if there is a linear staining of tubular basement membranes for IgG. Interstitial edema with infiltration of inflammatory cells is predominant in the acute phase, whereas interstitial fibrosis is revealed in the chronic phase. Interstitial infiltrates are composed of neutrophils, eosinophils, lymphocytes, monocytes and macrophages. If Bowman's capsules are disrupted, inflammatory cells infiltrate around glomeruli and have a granulomatous appearance. Acute inflammation of renal vessels,

except for glomerular capillaries, is not typical for anti-GBM disease, unless the case has concurrent ANCA (Bosch et al., 1991).

Fig. 4. Previous investigations of crescent formation in anti-GBM disease and ANCA-associated vasculitis.

Each bar shows the frequency of patients with 50% or more crescents in anti-GBM disease (purple) and ANCA-associated vasculitis (blue). The numbers show the mean percentage of glomeruli showing crescent formation in anti-GBM disease. Abbreviations: UK, United Kingdom; USA, United States; NZ, New Zealand.

7.2 Immunofluorescence findings

The immunohistologic feature of anti-GBM disease is linear staining of the glomerular capillary walls for IgG (Figure 5). IgG1 is the predominant IgG subclass in staining of the glomerular capillary walls (Bowman et al., 1987; Segelmark et al., 1990). Linear staining for IgM and IgA is less common, but rare cases with anti-GBM disease have linear staining only for IgA and circulating IgA-class anti-GBM antibodies in the absence of IgG-class anti-GBM antibodies in the serum or staining in glomeruli (Border et al., 1979; Gris et al., 1991; Borza et al., 2005). Granular or discontinuous linear staining for C3 is observed in most cases with anti-GBM disease, but glomerular staining for C3 is negative for some cases (Wilson and Dixon, 1973). Irregular staining for fibrin is observed in portions of glomerular necrosis and cellular crescents.

Linear staining of tubular basement membranes for IgG sometimes occurs (Lehman et al., 1975; Andres et al., 1978).

Fig. 5. Direct immunofluorescence for IgG in a patient with anti-GBM disease.

Linear staining for IgG along glomerular capillary walls is observed, but staining for IgG at the part of the cellular crescent is not.

7.3 Electroscopic findings

The rupture of GBM with variable degrees of endothelial swelling and lucent expansion of the subendothelial zone is common ultrastructural findings in the acute phase of anti-GBM disease. Rupture of Bowman's capsule, focal effacement of epithelial foot processes and accumulation of epithelial cells and macrophages in Bowman's spaces are also observed. Occasionally, neutrophils are identified in capillaries, especially at sites where GBM is disrupted. Those findings are also observed in pauci-immune crescentic glomerulonephritis, but electron-dense deposits are absent, unlike the case with immune complex-type crescentic glomerulonephritis.

8. Treatments

As the pathogenesis of anti-GBM disease became clear, treatment regimens were designed to remove the circulating pathogenic anti-GBM antibodies by therapeutic plasma exchange, attenuate the pathogenic antibody-mediated glomerular inflammatory responses by administration of corticosteroids and suppress further production of these pathogenic antibodies by the use of immunosuppressive agents.

8.1 Therapeutic plasmapheresis

To remove the circulating pathogenic anti-GBM antibodies, therapeutic plasma exchange is recommended as the initial treatment. The effectiveness of therapeutic plasmapheresis for improving renal function has been reported. In the most commonly used regimens, plasma exchange of 4 L of plasma for 5% human albumin was performed daily for 14 days or until

the circulating anti-GBM antibodies were no longer detected (Lockwood et al., 1976). In the presence of alveolar hemorrhage, 300-400 ml of fresh-frozen plasma was given at the end of each treatment.

To reduce the replacement of plasma, anti-GBM antibody removal has been modified. Immunoabsorption to remove circulating IgG immunoglobulins without the need for protein substitution during daily treatments may also be beneficial in Goodpasture's disease. Anecdotal case reports suggest that it may be an alternative to plasmapheresis in patients with severe renal failure (Laczika et al., 2000). There was a case report of Goodpasture's syndrome that we treated with double filtration plasmapheresis combined with immunosuppression therapy (Nagasu et al., 2009). In that therapy, the removal efficiency for the anti-GBM antibody was 24 to 60% for each procedure.

8.2 Corticosteroids

To attenuate the pathogenic antibody-mediated glomerular inflammatory responses, corticosteroid is also a key element of this treatment. According to the most commonly used regimens, oral dosing of prednisolone at 1 mg/kg/day ideal body weight (maximum 80 mg daily) continues for at least 2 weeks, after which the dose is reduced every second week to 30 mg by 8 weeks. After that, the dosages of prednisolone are tapered to 2.5-5.0 mg/week and maintained at 7.5-10 mg/kg/day. Oral corticosteroids have generally been continued for at least 6 months. Intravenous administration of methylprednisolone 10 mg/kg (500-1000 mg) once daily for 1-3 days has been advocated for patients with severe alveolar hemorrhage or very rapid deterioration of renal function (Johnson et al., 1985).

8.3 Immunosuppressive agents

To further suppress the production of pathogenic anti-GBM antibodies, a combination of immunosuppressive agents is usually given. Among these immunosuppressive agents, cyclophosphamide is usually administered. According to the most commonly used regimens, the oral dose is 2-3 mg/kg/day (this is rounded down to the nearest 50 mg; reduced to 2 mg/kg/day in patients over 55 years) for 3 months. This administration is stopped if white blood cell counts fall below 4,000/ μ L. In such cases the agent is restarted at a lower dose once the white blood cell counts return above 4,000/ μ L. Intravenous cyclophosphamide (IVCY) is not usually administered, but it may be useful for a refractory case of the standard therapy (Baumgartner et al., 1995).

Although azathioprine is sometimes used as maintenance therapy, it alone does not provide adequate immunosuppression to modify the disease.

8.4 Therapeutic options for refractory diseases

There is very little study on the treatment of refractory anti-GBM disease. Cyclosporine is controversial; at 6 mg/kg/day it was effective for an anti-GBM disease patient treated with corticosteroid, cyclophosphamide and plasma exchange (Querín et al., 1992), whereas it was not useful (Pepys et al., 1982). Small numbers of case reports of successful outcomes with mycophenolic acid or mycophenolate mofetil in patients unresponsive to or intolerant of standard therapy have been published (García-Cantón et al., 2000; Kiykim et al., 2010; Malho et al., 2010). Rituximab, a chimeric monoclonal anti-CD20 antibody, was effective for a case of relapsed anti-GBM disease that was resistant to standard treatment (Arzoo et al., 2002). In that case, rituximab (375 mg/m²) was administered once a week for 6 consecutive weeks; the symptoms completely resolved and anti-GBM antibody titers were decreased from 51 U/mL

to the undetectable range. However, these treatments cannot yet be recommended as a first-line therapy because no randomized controlled trials have been carried out.

9. Prognosis

Most patients without treatment died shortly after diagnosis of anti-GBM disease; the survival rate at 12 months was 4%, and the renal survival rate was 2% (Benoit et al., 1963). Although mortality has improved by the introduction of intense immunosuppression, renal survival remains very poor because of the delayed diagnosis of anti-GBM disease or delayed initiation of induction therapies.

9.1 Outcomes

The prognosis for patients with anti-GBM disease is poor; the survival rate at 6-12 months was 67-94%, but the renal survival rate was 15-58% in Europe, the United States, China and Japan (Table 4).

Authors	Year	Nation	Treatment	N	AH (%)	1-year survival (%)	
						Patient	Renal
Herody et al.	1993	France	OCS+CYC+AZA	29	50	93	41
Lazor et al.	2007	France & Switzerland	OCS+CYC+PE	24	100	100	58
Merkel et al.	1994	Germany	OCS+CYC+PE	35	57	89	29
Daly et al.	1996	Ireland	IS+PE	40	67	98	20
Segelmark et al.	2003	Sweden	OCS+CYC+PE	79	24	66	25
Peters et al.	1982	United Kingdom	IS+PE	41	56	76	39
Savage et al.	1986	United Kingdom	IS+PE	108	52	78	20
Levy et al.	2001	United Kingdom	OCS+CYC+PE	71	62	77	53
Proskey et al.	1970	United States	IS	56	100	77	23
Wilson et al.	1973	United States	IS	53	60	53	13
Beirne et al.	1977	United States	IS	29	54	42	17
Briggs et al.	1979	United States	IS(+PE)	18	61	84	22
Johnson et al	1985	United States	OCS+CYC	9	78	89	22
			OCS+CYC+PE	8	100	100	75
Walker et al.	1985	Australia	IS+PE	22	62	59	45
Teague et al.	1978	New Zealand	IS+PE	29	100	64	31
			no treatment	8	100	63	25
Simpson et al.	1982	New Zealand	OCS+AZA	4	100	100	50
			OCS+CYC+PE	8	100	100	63
Li et al.	2004	China (Hong Kong)	IS+PE	10	40	70	15
Cui et al.	2005	China	IS+PE	97	58	92	22
			OCS+CYC	21	14	86	24
Hirayama et al	2008	Japan	OCS+CYC	21	14	86	24
			OCS+CYC+PE	22	36	68	14

Abbreviations: N, number of patients; AH, alveolar hemorrhage; IS, immunosuppressants (including methylprednisolone pulse therapy, oral corticosteroids, cyclophosphamide or azathioprine); PE, plasma exchange; OCS, oral corticosteroids; CYC, cyclophosphamide; AZA, azathioprine.

Table 4. Investigations of treatments for anti-GBM antibody disease.

Renal function improves in 15-75% of patients with anti-GBM disease through the combination of plasma exchange with corticosteroids and immunosuppressive agents, whereas the renal survival rates of anti-GBM disease patients treated with immunosuppressive agents alone ranged from 2-22%. Improvement of renal function is usually evident within days of the start of plasma exchange. However, it should be emphasized that this regimen has never been properly assessed by a prospective randomized controlled trial because of the rarity and acuteness of the condition. The only reported randomized controlled trial was very small and used lower doses of both plasma exchange and cyclophosphamide than those that are generally used in practice.

Although the effectiveness of treatment using therapeutic plasma exchange combined with immunosuppressive agents to improve renal function has been reported, only half of patients with anti-GBM disease had been treated with plasma exchange in our survey (Hirayama et al., 2008). Therefore, there was no significant difference in the renal survival rates between anti-GBM antibody disease patients treated with and without plasma exchange ($P = 0.683$ by the Log-rank Mantel-Cox test). Moreover, there was no significant difference in mortality between anti-GBM antibody disease patients treated with and without plasma exchange ($P = 0.109$).

9.2 Predictors of survival

The best predictors of renal survival are s-Cr at the initiation of treatment and the mean percentage of crescent formations. Renal function improves coincidentally with the introduction of plasma exchange in about 80-95% of patients with s-Cr levels less than or equal to 5.7-6.8 mg/dL (500-600 $\mu\text{mol/L}$), but in far fewer of those with higher s-Cr levels or those who require dialysis. Unfortunately, most patients with anti-GBM disease had renal failure at the time of diagnosis, and the mean percentage of crescent formation was high in anti-GBM disease patients. Therefore, in most patients with anti-GBM disease, the diagnosis may have been made too late to improve renal function by combination therapy.

9.3 Relapse/recurrence

Relapses of anti-GBM disease are rarely observed, in contrast to most other autoimmune kidney diseases. The anti-GBM antibodies seem to disappear spontaneously after 12-18 months (Levy et al., 1996). However, several reports demonstrated recurring cases with anti-GBM disease (Adler et al., 1981; Hind et al., 1984; Klasa et al., 1988; Levy et al., 1996). In our survey (Hirayama et al., 2008), relapse or recurrence was also rare in patients with anti-GBM disease (13.9%) in comparison with patients with ANCA-associated vasculitis, such as WG (29.4%) and MPA (29.3%). Therefore, remission induction therapy is more important in anti-GBM disease. The mean time to recurrence is estimated to be 4.3 years (range, 1-10 years), and that late recurrence may occur with a frequency of 2-14%. During relapses, circulating anti-GBM antibodies often reappear. The combination of plasmapheresis and immunosuppressive agents as re-remission induction therapy is also successful in relapsing cases (Levy et al., 1996).

10. Conclusion

Anti-GBM disease is a rare but well-characterized glomerulonephritis. It occurs across all racial groups but is most common in Caucasians. Although the effectiveness of treatment using therapeutic plasma exchange combined with immunosuppressive agents to improve

renal function has been reported, the prognosis for patients with this disease is poor. To improve the prognosis, it may be necessary to detect this disease in earlier stages and to treat it without delay.

11. Acknowledgment

The authors acknowledge the participants in this Japanese nationwide survey and the members of the RPGN Clinical Guidelines Committee of Japan. The authors thank Dr. Miho Nagai, Dr. Yujiro Ogawa, Dr. Shogo Fujita, Dr. Homare Shimohata and Prof. Masaki Kobayashi (Tokyo Medical University Ibaraki Medical Center) and Dr. Joichi Usui (University of Tsukuba) for their assistance. The Japanese nationwide RPGN survey was supported by a grant-in-aid from the Research Fund for the Special Study Group on Progressive Glomerular Disease, the Ministry of Health, Labor and Welfare, Japan.

12. References

- Adler, S.; Bruns, F.J., Fraley, D.S. & Segel, D.P. (1981). Rapid progressive glomerulonephritis: relapse after prolonged remission. *Archives of Internal Medicine*, Vol.141, No.7, (June 1981), pp. 852-854, ISSN 0003-9926
- Adler, S.; Chen, X. & Eng, B. (1990). Control of rat glomerular epithelial cell growth in vitro. *Kidney International*, Vol.37, No.4, (April 1990), pp. 1048-1054, ISSN 0085-2538
- Andrassy, K.; Küster, S., Waldherr, R. & Ritz, E. (1991). Rapidly progressive glomerulonephritis: analysis of prevalence and clinical course. *Nephron*, Vol.59, No.2, (October 1991), ISSN 0028-2766
- Andres, G.; Brentjens, J., Kohli, R., Anthone, R., Anthone, S., Baliah, T., Montes, M., Mookerjee, B.K., Prezyna, A., Sepulveda, M., Venuto, R. & Elwood, C. (1978). Histology of human tubulo-interstitial nephritis associated with antibodies to renal basement membranes. *Kidney International*, Vol.13, No. 6, (June 1978), pp. 480-491, ISSN 0085-2538
- Anganco, R.; Thiru, S., Esnault, V.L., Short, A.K., Lockwood, C.M. & Oliveira, D.B. (1994). Does truly 'idiopathic' crescentic glomerulonephritis exist? *Nephrology Dialysis Transplantation*, Vol.9, No.6, (June 1994), pp.630-636, ISSN 0931-0509
- Arzoo, K.; Sadeghi, S. & Liebman, H.A. (2002). Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). *Annals of the Rheumatic Diseases*, Vol.61, No.10, (October 2002), pp. 922-924, ISSN 0003-4967
- Atkins, R.C.; Holdsworth, S.R., Glasgow, E.F. & Matthews, F.E. (1976). The macrophage in human rapidly progressive glomerulonephritis. *The Lancet*, Vol.1, No.7964, (April 1976), pp. 830-832, ISSN 0140-6736
- Baricos, W.H.; Cortez, S.L., Le, Q.C., Wu, L.T., Shaw, E., Hanada, K. & Shah, S.V. (1991). Evidence suggesting a role for cathepsin L in an experimental model of glomerulonephritis. *Archives of Biochemistry and Biophysics*, Vol.288, No.2, (August 1991), pp. 468-472, ISSN 0003-9861
- Baumgartner, I.; Gmür, J., Fontana, A., Widmer, U. & Walter, E. (1995). Recovery from life threatening pulmonary hemorrhage in Goodpasture's syndrome after plasmapheresis and subsequent pulse dose cyclophosphamide. *Clinical Nephrology*, Vol.43, No.1, (January 1995), pp. 68-70, ISSN 0301-0430

- Beirne, G.J.; Wagnild, J.P., Zimmerman, S.W., Macken, P.D. & Burkholder, P.M. (1977). Idiopathic crescentic glomerulonephritis. *Medicine (Baltimore)*, Vol.56, No.5, (September 1977), pp.349–381, ISSN 0025-7974
- Beirne, G.J. & Brennan J.T. (1972). Glomerulonephritis associated with hydrocarbon solvents: mediated by antiglomerular basement membrane antibody. *Archives of Environmental Health*, Vol.25, No.5, (November 1972), pp. 365–369, ISSN 0003-9896
- Benoit, F.L.; Rulon, D.B., Theil, G.B., Doolan, P.D. & Watten, R.H. (1963). Goodpasture's syndrome: A clinicopathologic entity. *The American Journal of Medicine*, Vol.58, (September 1963), pp. 424–444, ISSN 0002-9343
- Blue, W.T. & Lange, C.F (1975). Increased immunologic reactivity between human glomerular basement membrane and group A type 12 streptococcal cell membrane after carbohydrase treatment. *Journal of Immunology*, Vol.114, No.1, (January 1975), pp. 306–309, ISSN 0022-1767
- Bombassei, G.J. & Kaplan, A.A. (1992). The association between hydrocarbon exposure and anti-glomerular basement membrane antibody-mediated disease (Goodpasture's syndrome). *American Journal of Industrial Medicine*, Vol.21, No.2, (February 1992), pp. 141–153, ISSN 0271-3586
- Bonzel, K.E.; Müller-Wiefel, D.E., Ruder, H., Wingen, A.M., Waldherr, R. & Weber, M. (1987). Anti-glomerular basement membrane antibody-mediated glomerulonephritis due to glue sniffing. *European Journal of Pediatrics*, Vol.146, No.3, (May 1987), pp. 296–300, ISSN 0340-6199
- Border, W.A.; Baehler, R.W., Bhathena, D. & Glassock, R.J. (1979). IgA antibasement membrane nephritis with pulmonary hemorrhage. *Annals of Internal Medicine*, Vol.91, No.1, (July 1979), pp. 21–25, ISSN 0003-4819
- Borza, D.B.; Netzer, K.O., Leinonen, A., Todd, P., Cervera, J., Saus, J. & Hudson, B.G. (2000). The Goodpasture autoantigen. Identification of multiple cryptic epitopes on the NC1 domain of the alpha3(IV) collagen chain. *The Journal of Biological Chemistry*, Vol.275, No.8, (February 2000), pp. 6030–6037, ISSN 0021-9258
- Borza, D.B.; Chedid, M.F., Colon, S., Lager, D.J., Leung, N. & Fervenza, F.C. (2005). Recurrent Goodpasture's disease secondary to a monoclonal IgA1-kappa antibody autoreactive with the alpha1/alpha2 chains of type IV collagen. *American Journal of Kidney Diseases*, Vol.45, No.2, (February 2005), pp. 397–406, ISSN 0272-6386
- Bosch, X.; Mirapeix, E., Font, J., Borrellas, X., Rodríguez, R., López-Soto, A., Ingelmo, M. & Revert, L. (1991). Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with myeloperoxidase specificity in anti-glomerular basement membrane disease. *Clinical Nephrology*, Vol.36, No.3, (September 1991), pp. 107–113, ISSN 0301-0430
- Boucher, A.; Droz, D., Adafer, E. & Noel, L.H. (1987). Relationship between the integrity of Bowman's capsule and the composition of cellular crescents in human crescentic glomerulonephritis. *Laboratory Investigation*, Vol.56, No.5, (May 1987), pp. 526–533, ISSN 0023-6837
- Bowman, C.; Ambrus, K. & Lockwood, C.M. (1987). Restriction of human IgG subclass expression in the population of auto-antibodies to glomerular basement membrane. *Clinical and Experimental Immunology*, Vol.69, No.2, (August 1987), pp. 341–349, ISSN 0009-9104

- Briganti, E.M.; Dowling, J., Finlay, M., Hill, P.A., Jones, C.L., Kincaid-Smith, P.S., Sinclair, R., McNeil, J.J. & Atkins, R.C. (2001). The incidence of biopsy-proven glomerulonephritis in Australia. *Nephrology Dialysis Transplantation*, Vol.16, No.7, (July 2001), pp. 1364-1367, ISSN 0931-0509
- Briggs, W.A.; Johnson, J.P., Teichman, S., Yeager, H.C. & Wilson, C.B. (1979). Antiglomerular basement membrane antibody-mediated glomerulonephritis and Goodpasture's syndrome. *Medicine (Baltimore)*, Vol.58, No.5, (September 1979), pp. 348-361, ISSN 0025-7974
- Churchill, D.N.; Fine, A. & Gault, M.H. (1983). Association between hydrocarbon exposure and glomerulonephritis. An appraisal of the evidence. *Nephron*, Vol.33, No.3, (June 1983), pp. 169-172, ISSN 0028-2766
- Clatworthy, M.R.; Wallin, E.F. & Jayne, D.R. (2008). Anti-glomerular basement membrane disease after alemtuzumab. *The New England Journal of Medicine*, Vol.359, No.7, (August 2008), pp. 768-769, ISSN 0028-4793
- Cui, Z.; Zhao, M.H., Xin, G. & Wang, H.Y. (2005). Characteristics and prognosis of Chinese patients with anti-glomerular basement membrane disease. *Nephron Clinical Practice*, Vol.99, No.2, (February 2005), pp. c49-c55, ISSN 1660-2110
- Daly, C.; Conlon, P.J., Medwar, W. & Walshe, J.J. (1996). Characteristics and outcome of anti-glomerular basement membrane disease: a single-center experience. *Renal Failure*, Vol.18, No.1, (January 1996), pp. 105-112, ISSN 0886-022X
- Date, A.; Raghavan, R., John, T.J., Richard, J., Kirubakaran, M.G. & Shastry, J.C.N. (1987). Renal disease in adult Indians: a clinicopathological study of 2827 patients. *The Quarterly Journal of Medicine*, Vol.64, No.245, (September 1987), pp. 729-737, ISSN 0033-5622
- Donaghy, M. & Rees, A.J. (1983). Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane. *The Lancet*, Vol. 2, No.8364, (December 1983), pp. 1390-1393, ISSN 0140-6736
- Fisher, M.; Pusey, C.D., Vaughan, R.W. & Rees, A.J. (1997). Susceptibility to anti-glomerular basement membrane disease is strongly associated with HLA-DRB1 genes. *Kidney International*, Vol.51, No.1, (January 1997), pp. 222-229, ISSN 0085-2538
- Fischer, E.G. & Lager, D.J. (2006). Anti-glomerular basement membrane glomerulonephritis: a morphologic study of 80 cases. *American Journal of Clinical Pathology*, Vol.123, No.3, (March 2006), pp. 445-450, ISSN 0002-9173
- García-Cantón, C.; Toledo, A., Palomar, R., Fernandez, F., Lopez, J., Moreno, A., Esparza, N., Suria, S., Rossique, P., Diaz, J.M. & Checa, D. (2000). Goodpasture's syndrome treated with mycophenolate mofetil. *Nephrology Dialysis Transplantation*, Vol.15, No.6, (June 2000), pp. 920-922, ISSN 0931-0509
- García-Rostan y Pérez, G.M.; García Bragado, F. & Puras Gil, A.M. (1997). Pulmonary hemorrhage and anti-glomerular basement membrane antibody-mediated glomerulonephritis after exposure to smoked cocaine (crack): a case report and review of the literature. *Pathology International*, Vol.47, No.10, (October 1997), pp. 692-697, ISSN 1320-5463
- Goodpasture E.W. (1919). The significance of certain pulmonary lesions in relation to the etiology of influenza. *The American Journal of the Medical Sciences*, Vol.158, No.6, (1919), pp. 863-870, (republished in *The American Journal of the Medical Sciences*, Vol.338, No.2, (August 2009), pp. 148-151), ISSN 0002-9629

- Grcevska, L. & Polenakovic, M. (1995). Crescentic glomerulonephritis as renal cause of acute renal failure. *Renal Failure*, Vol.17, No.5, (September 1995), pp. 595-604, ISSN 0886-022X
- Gris, P.; Pirson, Y., Hamels, J., Vaerman, J.P., Quoidbach, A. & Demol, H. (1991). Antiglomerular basement membrane nephritis induced by IgA1 antibodies. *Nephron*, Vol.58, No.4, (August 1991), pp. 418-424, ISSN 0028-2766
- He, C.J.; Rondeau, E., Medcalf, R.L., Lacave, R., Schleuning, W.D. & Sraer, J.D. (1991). Thrombin increases proliferation and decreases fibrinolytic activity of kidney glomerular epithelial cells. *Journal of Cellular Physiology*, Vol.146, No.1, (January 1991), pp. 131-140, ISSN 0021-9541
- Heaf, J.; Løkkegaard, H. & Larsen, S. (1999). The epidemiology and prognosis of glomerulonephritis in Denmark 1985-1997. *Nephrology Dialysis Transplantation*, Vol.14, No.8, (August 1999), pp. 1889-1897, ISSN 0931-0509
- Herody, M.; Bobrie, G., Gouarin, C., Grünfeld, J.P. & Noel, L.H. (1993). Anti-GBM disease: Predictive value of clinical, histological and serological data. *Clinical Nephrology*, Vol.40, No.5, (November 1993), pp. 249-255, ISSN 0301-0430
- Hind, C.R.K.; Bowman, C., Winearles, C.G. & Lockwood, C.M. (1984). Recurrence of circulating anti-glomerular basement membrane antibody three years after immunosuppressive treatment and plasma exchange. *Clinical Nephrology*, Vol.21, No.4, (April 1984), pp. 244-246, ISSN 0301-0430
- Holdsworth, S.; Boyce, N., Thomson, N.M. & Atkins, R.C. (1985). The clinical spectrum of acute glomerulonephritis and lung haemorrhage (Goodpasture's syndrome). *The Quarterly Journal of Medicine*, Vol.55, No.216, (April 1985), pp. 75-86, ISSN 0033-5622
- Hudson, B.G.; Tryggvason, K., Sundaramoorthy, M. & Neilson, E.G. (2003). Alport's syndrome, Goodpasture's syndrome, and type IV collagen. *The New England Journal of Medicine*, Vol.348, No.25, (June 2003), pp. 2543-2556, ISSN 0028-4793
- Jayne, D.R.; Marshall, P.D., Jones, S.J. & Lockwood, C.M. (1990). Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. *Kidney International*, Vol.37, No.3, (March 1990), pp. 965-970, ISSN 0085-2538
- Jennette, J.C. (2003). Rapidly progressive crescentic glomerulonephritis. *Kidney International*, Vol.63, No.3, (March 2003), pp. 1164-1177, ISSN 0085-2538
- Johnson, J.P.; Moore, J. Jr., Austin, H.A. 3rd, Balow, J.E., Antonovych, T.T. & Wilson, C.B. (1985). Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors. *Medicine (Baltimore)*, Vol.64, No.4, (July 1985), pp. 219-227, ISSN 0025-7974
- Kalluri, R.; Sun, M.J., Hudson, B.G. & Neilson, E.G. (1996). The Goodpasture autoantigen. Structural delineation of two immunologically privileged epitopes on alpha3(IV) chain of type IV collagen. *The Journal of Biological Chemistry*, Vol.271, No.15, (April 1996), pp. 9062-9068, ISSN 0021-9258
- Kaneko, Y.; Sakatsume, M., Xie, Y., Kuroda, T., Igashima, M., Narita, I. & Gejyo, F. (2003). Macrophage metalloelastase as a major factor for glomerular injury in anti-glomerular basement membrane nephritis. *Journal of Immunology*, Vol.170, No.6, (March 2003), pp. 3377-3385, ISSN 0022-1767
- Kitagawa, W.; Imai, H., Komatsuda, A., Maki, N., Wakui, H., Hiki, Y. & Sugiyama, S. (2008). The HLA-DRB1*1501 allele is prevalent among Japanese patients with anti-

- glomerular basement membrane antibody-mediated disease. *Nephrology Dialysis Transplantation*, Vol. 23, No.10, (October 2008), pp. 3126-3129, ISSN 0931-0509
- Kitching, A.R., Tipping, P.G. & Holdsworth, S.R. (1999). IL-12 directs severe renal injury, crescent formation and Th1 responses in murine glomerulonephritis. *European Journal of Immunology*, Vol.29, No.1, (January 1999), pp. 1-10, ISSN 0014-2980
- Kiykim, A.A.; Horoz, M. & Gok, E. (2010). Successful treatment of resistant anti-glomerular basement membrane antibody positivity with mycophenolic acid. *Internal Medicine*, Vol.49, No.6, (June 2010), pp. 577-580, ISSN 0918-2918
- Klasa, R.J.; Abboud, R.T., Ballon, H.S. & Grossman, L. (1988). Goodpasture's syndrome: recurrence after a five-year remission. Case report and review of the literature. *The American Journal of Medicine*, Vol.84, No.4, (April 1988), pp. 751-755, ISSN 0002-9343
- Laczika, K.; Knapp, S., Derfler, K., Soleiman, A., Horl, W.H. & Druml, W. (2000). Immunoabsorption in Goodpasture's syndrome. *American Journal of Kidney Diseases*, Vol.36, No.2, (August 2000), pp. 392-395, ISSN 0272-6386
- Lan, H.Y.; Nikolic-Paterson, D.J., Zarama, M., Vannice, J.L. & Atkins, R.C. (1993). Suppression of experimental crescentic glomerulonephritis by the interleukin-1 receptor antagonist. *Kidney International*, Vol.43, No.2, (February 1993), pp. 479-485, ISSN 0085-2538
- Lan, H.Y.; Yang, N., Metz, C., Mu, W., Song, Q., Nikolic-Paterson, D.J., Bacher, M., Bucala, R. & Atkins, R.C. (1997). TNF-alpha up-regulates renal MIF expression in rat crescentic glomerulonephritis. *Molecular Medicine*, Vol.3, No.2, (February 1997), pp. 136-144, ISSN 1076-1551
- Lazor, R.; Bigay-Gamé, L., Cottin, V., Cadranel, J., Decaux, O., Fellrath, J.M. & Cordier, J.F.; Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires (GERMOP); Swiss Group for Interstitial and Orphan Lung Diseases (SIOLD). (2007). Alveolar hemorrhage in anti-basement membrane antibody disease: a series of 28 cases. *Medicine (Baltimore)*, Vol.86, No.3, (March 2007), pp. 181-193, ISSN 0025-7974
- Le Hir, M.; Haas, C., Marino, M. & Ryffel, B. (1998). Prevention of crescentic glomerulonephritis induced by anti-glomerular membrane antibody in tumor necrosis factor-deficient mice. *Laboratory Investigation*, Vol.78, No.12, (December 1998), pp. 1625-1631, ISSN 0023-6837
- Lechleitner, P.; Defregger, M., Lhotta, K., Tötsch, M. & Fend, F. (1993). Goodpasture's syndrome. Unusual presentation after exposure to hard metal dust. *Chest*, Vol.103, No.3, (March 1993), pp. 956-957, ISSN 0012-3692
- Lehman, D.H.; Wilson, C.B. & Dixon, F.J. (1975). Extraglomerular immunoglobulin deposits in human nephritis. *American Journal of Medicine*, Vol.58, No.6, (June 1975), pp. 765-796, ISSN 0002-9343
- Lerner, R.A.; Glasscock, R.J. & Dixon, F.J. (1967). The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. *The Journal of Experimental Medicine*, Vol.126, No.6, (December 1967), pp. 989-1004. 0022-1007
- Levy, J.B.; Lachmann, R.H. & Pusey, C.D. (1996). Recurrent Goodpasture's disease. *American Journal of Kidney Diseases*, Vol.27, No.4, (April 1996), pp. 573-578, ISSN 0272-6386
- Levy, J.B.; Turner, A.N., Rees, A.J. & Pusey, C.D. (2001). Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange

- and immunosuppression. *Annals of Internal Medicine*, Vol.134, No.11, (June 2001), pp. 1033-1042, ISSN 0003-4819
- Levy, J.B.; Hammad, T., Coulthart, A., Dougan, T. & Pusey, C.D. (2004). Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. *Kidney International*, Vol.66, No.4, (October 2004), pp. 1535-1540, ISSN 0085-2538
- Li, F.K.; Tse, K.C., Lam, M.F., Yip, T.P., Lui, S.L., Chan, G.S., Chan, K.W., Chan, E.Y., Choy, B.Y., Lo, W.K., Chan, T.M. & Lai, K.N. (2004). Incidence and outcome of antiglomerular basement membrane disease in Chinese. *Nephrology (Carlton)*, Vol.9, No.2, (April 2004), pp. 100-104, ISSN 1320-5358
- Li, L.S. & Liu, Z.H. (2004). Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. *Kidney International*, Vol.66, No.3, (September 2004), pp. 920-923, ISSN 0085-2538
- Liu, K.; Li, Q.Z., Delgado-Vega, A.M., Abelson, A.K., Sánchez, E., Kelly, J.A., Li, L., Liu, Y., Zhou, J., Yan, M., Ye, Q., Liu, S., Xie, C., Zhou, X.J., Chung, S.A., Pons-Estel, B., Witte, T., de Ramón, E., Bae, S.C., Barizzzone, N., Sebastiani, G.D., Merrill, J.T., Gregersen, P.K., Gilkeson, G.G., Kimberly, R.P., Vyse, T.J., Kim, I., D'Alfonso, S., Martin, J., Harley, J.B., Criswell, L.A.; Profile Study Group; Italian Collaborative Group; German Collaborative Group; Spanish Collaborative Group; Argentinian Collaborative Group; SLEGEN Consortium, Wakeland, E.K., Alarcón-Riquelme, M.E. & Mohan, C. (2009). Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans. *The Journal of Clinical Investigation*, Vol.119, No.4, (April 2009), pp. 911-923, ISSN 0021-9738
- Lockwood, C.M.; Rees, A.J., Pearson, T.A., Evans, D.J., Peters, D.K. & Wilson, C.B. (1976). Immunosuppression and plasma-exchange in the treatment of Goodpasture's syndrome. *The Lancet*, Vol.1, No.7962, (April 1976), pp. 711-715, ISSN 0140-6736
- Malho, A.; Santos, V., Cabrita, A., Silva, A.P., Pinto, I., Bernardo, I. & Neves, P.L. (2010). Severe relapsing Goodpasture's disease successfully treated with mycophenolate mofetil. *International Journal of Nephrology*, Vol.16, (August 2010), pp. 383-488, ISSN 2090-2158
- Masugi, M. (1939). Über die experimentelle glomerulonephritis durch das spezifische antinieren serum. Ein beiträg zur pathogenese der diffusen glomerulonephritis. *Beiträge zur pathologischen anatomie und allgemeinen pathologie*, Vol.92, pp. 429-466
- Merkel, F.; Pullig, O., Marx, M., Netzer, K.O. & Weber, M. (1994). Course and prognosis of anti-basement membrane antibody (anti-BM-Ab)-mediated disease: Report of 35 cases. *Nephrology Dialysis Transplantation*, Vol.9, No.4, (April 1994), pp. 372-376, ISSN 0931-0509
- Min, K.W.; Györkey, F., Györkey, P., Yium, J.J. & Eknoyan, G. (1974). The morphogenesis of glomerular crescents in rapidly progressive glomerulonephritis. *Kidney International*, Vol.5, No.1, (January 1974), pp. 47-56, ISSN 0085-2538
- Morita, T.; Suzuki, Y. & Churg, J. (1973). Structure and development of the glomerular crescent. *The American Journal of Pathology*, Vol.72, No.3, (September 1973), pp. 349-368, ISSN 0002-9440
- Nagasu, H., Abe, M., Kuwabara, A., Kawai, T., Nishi, Y., Okuda, N. & Sakaguchi, K. (2009). A case report of efficiency of double filtration plasmapheresis in treatment of

- Goodpasture's syndrome. *Therapeutic Apheresis and Dialysis*, Vol.13, No.4, (August 2009), pp. 373-377, ISSN 1744-9979
- Naumovic, R.; Pavlovic, S., Stojkovic, D., Basta-Jovanovic, G. & Nesic, V. (2009). Renal biopsy registry from a single centre in Serbia: 20 years of experience. *Nephrology Dialysis Transplantation*, Vol.24, No.3, (March 2009), pp. 877-885, ISSN 0931-0509
- Netzer, K.O.; Leinonen, A., Boutaud, A., Borza, D.B., Todd, P., Gunwar, S., Langeveld, J.P. & Hudson, B.G. (1999). The Goodpasture autoantigen. Mapping the major conformational epitope(s) of alpha3(IV) collagen to residues 17-31 and 127-141 of the NC1 domain. *The Journal of Biological Chemistry*, Vol.274, No.16, (April 1999), pp. 11267-11274, ISSN 0021-9258
- The New Zealand Glomerulonephritis Study Group. (1989). The New Zealand Glomerulonephritis Study: introductory report. *Clinical Nephrology*, Vol.31, No.5, (May 1989), pp. 239-246, ISSN 0301-0430
- Ooi, J.D.; Holdsworth, S.R. & Kitching, A.R. (2008). Advances in the pathogenesis of Goodpasture's disease: from epitopes to autoantibodies to effector T cells. *Journal of Autoimmunity*, Vol.31, No.3, (November 2008), pp. 295-300, ISSN 0896-8411
- Ophascharoensuk, V.; Pippin, J.W., Gordon, K.L., Shankland, S.J., Couser, W.G. & Johnson, R.J. (1998). Role of intrinsic renal cells versus infiltrating cells in glomerular crescent formation. *Kidney International*, Vol.54, No.2, (August 1998), pp. 416-425, ISSN 0085-2538
- Ortega, L.G. & Mellors, R.C. (1956). Analytical pathology. IV. The role of localized antibodies in the pathogenesis of nephrotoxic nephritis in the rat. *The Journal of Experimental Medicine*, Vol.104, No.1, (July 1956), pp. 151-157, ISSN 0022-1007
- Parfrey, P.S.; Hutchinson, T.A., Jothy, S., Cramer, B.C., Martin, J., Hanley, J.A. & Seely, J.F. (1985). The spectrum of disease associated with necrotizing glomerulonephritis and its prognosis. *American Journal of Kidney Diseases*, Vol.6, No.6, (December 1985), pp. 387-396, ISSN 0272-6386
- Pedchenko, V.; Bondar, O., Fogo, A.B., Vanacore, R., Voziyan, P., Kitching, A.R., Wieslander, J., Kashtan, C., Borza, D.B., Neilson, E.G., Wilson, C.B. & Hudson, B.G. (2010). Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. *The New England Journal of Medicine*, Vol.363, No.4, (July 2010), pp. 343-354, ISSN 0028-4793
- Pepys, E.O.; Rees, A.J. & Pepys, M.B. (1982). Enumeration of lymphocyte populations in whole peripheral blood of patients with antibody-mediated nephritis during treatment with cyclosporin A. *Immunology Letters*, Vol.4, No.4, (April 1982), pp. 211-214, ISSN 0165-2478
- Perez, G.O.; Bjornsson, S., Ross, A.H., Aamato, J. & Rothfield, N. (1974). A mini-epidemic of Goodpasture's syndrome clinical and immunological studies. *Nephron*, Vol.13, No.2, (August 1974), pp. 161-173, ISSN 0028-2766
- Persson, U.; Hertz, J.M., Carlsson, M., Hellmark, T., Juncker, I., Wieslander, J. & Segelmark, M. (2004). Patients with Goodpasture's disease have two normal COL4A3 alleles encoding the NC1 domain of the type IV collagen alpha 3 chain. *Nephrology Dialysis Transplantation*, Vol.19, No.8, (August 2004), pp. 2030-2035, ISSN 0931-0509
- Peters, D.K.; Rees, A.J., Lockwood, C.M. & Pusey, C.D. (1982). Treatment and prognosis in antibasement membrane antibody-mediated nephritis. *Transplantation Proceedings*, Vol.14, No.3, (September 1982), pp. 513-521, ISSN 0041-1345

- Phelps, R.G. & Rees, A.J. (1999). The HLA complex in Goodpasture's disease: a model for analyzing susceptibility to autoimmunity. *Kidney International*, Vol.56, No.5, (November 1999), pp. 1638-1653, ISSN 0085-2538
- Proskey, A.J.; Weatherbee, L., Easterling, R.E., Greene, J.A. Jr. & Weller, J.M. (1970). Goodpasture's syndrome. A report of five cases and review of the literature. *The American Journal of Medicine*, Vol.48, No.2, (February 1970), pp. 162-173, ISSN 0002-9343
- Pusey, C.D. (2003). Anti-glomerular basement membrane disease. *Kidney International*, Vol.64, No.4, (October 2003), pp. 1535-1550, ISSN 0085-2538
- Quérin, S.; Schürch, W. & Beaulieu, R. (1992). Ciclosporin in Goodpasture's syndrome. *Nephron*, Vol.60, No.3, (March 1992), pp. 355-359, ISSN 0028-2766
- Rees, A.J.; Peters, D.K., Compston, D.A. & Batchelor, J.R. (1978). Strong association between HLA-DRW2 and antibody-mediated Goodpasture's syndrome. *The Lancet*, Vol.1, No.8071, (May, 1978), pp. 966-968, ISSN 0140-6736
- Rees, A.J.; Demaine, A.G. & Welsh, K.I. (1984). Association of immunoglobulin Gm allotypes with antiglomerular basement membrane antibodies and their titer. *Human Immunology*, Vol.10, No.4, (August 1984), pp. 213-220, ISSN 0198-8859
- Rivera, F.; López-Gómez, J.M., Pérez-García, R. & Spanish Registry of Glomerulonephritis. (2002). Frequency of renal pathology in Spain 1994-1999. *Nephrology Dialysis Transplantation*, Vol.17, No.9, (September 2002), pp. 1594-1562, ISSN 0931-0509
- Rutgers, A.; Slot, M., van Paassen, P., van Breda Vriesman, P., Heeringa, P. & Tervaert, J.W. (2005). Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. *American Journal of Kidney Diseases*, Vol.46, No.2, (August 2005), pp. 253-262, ISSN 0272-6386
- Rychlík, I.; Jancová, E., Tesar, V., Kolsky, A., Lácha, J., Stejskal, J., Stejskalová, A., Dusek, J. & Herout V. (2004). The Czech registry of renal biopsies. Occurrence of renal diseases in the years 1994-2000. *Nephrology Dialysis Transplantation*, Vol.19, No.12, (December 2004), pp. 3040-3049, ISSN 0931-0509
- Sado, Y.; Kagawa, M., Naito, I., Ueki, Y., Seki, T., Momota, R., Ohashi, T. & Ninomiya, Y. (1998). Organization and expression of basement membrane collagen IV genes and their roles in human disorders. *Journal of Biochemistry*, Vol.123, No.5, (May 1998), pp. 767-776, ISSN 0021-924X
- Salama, A.D.; Levy, J.B., Lightstone, L. & Pusey, C.D. (2001). Goodpasture's disease. *The Lancet*, Vol.358, No.9285, (September 2001), pp. 917-920, ISSN 0140-6736
- Salant, D.J. (2010). Goodpasture's disease—new secrets revealed. *The New England Journal of Medicine*, Vol.363, No.4, (July 2010), pp. 388-391, ISSN 0028-4793
- Saus, J.; Wieslander, J., Langeveld, J.P., Quinones, S. & Hudson, B.G. (1988). Identification of the Goodpasture antigen as the $\alpha 3(\text{IV})$ chain of collagen IV. *The Journal of Biological Chemistry*, Vol.263, No.26, (September 1988), pp. 13374-13380, ISSN 0021-9258
- Savage, C.O.S.; Pusey, C.D., Bowman, C., Rees, A.J. & Lockwood, C.M. (1986). Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4. *British Medical Journal*, Vol.292, No.6516, (February 1986), pp. 301-304, ISSN 0267-0623
- Saxena, R.; Bygren, P., Rasmussen, N. & Wieslander, J. (1991). Circulating autoantibodies in patients with extracapillary glomerulonephritis. *Nephrology Dialysis Transplantation*, Vol.6, No.6, (June 1991), pp. 389-397, ISSN 0931-0509

- Scheer, R.L. & Grossman, M.A. (1964). Immune aspects of the glomerulonephritis associated with pulmonary hemorrhage. *Annals of Internal Medicine*, Vol. 60, No.6, (June 1964), pp. 1009-1021, ISSN 0003-4819
- Schena, F.P. & Survey of the Italian Registry of Renal Biopsies. (1997). Frequency of the renal diseases for 7 consecutive years. The Italian Group of Renal Immunopathology. *Nephrology Dialysis Transplantation*, Vol.12, No.3, (March 1997), pp. 418-426, ISSN 0931-0509
- Segelmark, M.; Butkowski, R. & Wieslander, J. (1990) Antigen restriction and IgG subclasses among anti-GBM autoantibodies. *Nephrology Dialysis Transplantation*, Vol.5, No.12, (December 1990), pp. 991-996, ISSN 0931-0509
- Segelmark, M.; Hellmark, T. & Wieslander, J. (2003) The prognostic significance in Goodpasture's disease of specificity, titre and affinity of anti-glomerular-basement-membrane antibodies. *Nephron Clinical Practice*, Vol.94, No., (2003), pp. c59-c68, ISSN 1660-2110
- Shah, M.K. & Hugghins, S.Y. (2002). Characteristics and outcomes of patients with Goodpasture's syndrome. *South Medical Journal*, Vol.95, No.12, (December 2002), pp. 1411-1418, ISSN 0038-4348
- Sheerin, N.S.; Springall, T., Carroll, M.C., Hartley, B. & Sacks, S.H. (1997). Protection against anti-glomerular basement membrane (GBM)-mediated nephritis in C3- and C4-deficient mice. *Clinical and Experimental Immunology*, Vol.110, No.3, (December 1997), pp. 403-409, ISSN 0009-9104
- Simpson, I.J.; Doak, P.B., Williams, L.C., Blacklock, H.A., Hill, R.S., Teague, C.A., Herdson, P.B. & Wilson, C.B. (1982). Plasma exchange in Goodpasture's syndrome. *American Journal of Nephrology*, Vol.2, No.6, (December 1982), pp.301-311, ISSN 0250-8095
- Stanton, M.C. & Tange, J.D. (1958). Goodpasture's syndrome (pulmonary haemorrhage associated with glomerulonephritis). *Australasian Annals of Medicine*, Vol.7, No.2, (May 1958), pp. 132-144, ISSN 0571-9283
- Sumethkul, V.; Changsirikulchai, S., Radinahamed, P. & Chalermasnyakorn, P. (1999). Antineutrophil cytoplasmic antibody (ANCA) and rapidly progressive crescentic glomerulonephritis in Thai population. *Asian Pacific Journal of Allergy and Immunology*, Vol.17, No.4, (December 1999), pp. 281-287, ISSN 0125-877X
- Tang, Z.; Wu, Y., Wang, Q., Zeng, C., Yao, X., Hu, W., Chen, H., Liu, Z. & Li, L. (2003). Clinical spectrum of diffuse crescentic glomerulonephritis in Chinese patients. *Chinese Medical Journal*, Vol.116, No.11, (2003), pp. 1737-1740, ISSN 0366-6999
- Teague, C.A.; Doak, P.B., Simpson, I.J., Rainer, S.P. & Herdson, P.B. (1978). Goodpasture's syndrome: an analysis of 29 cases. *Kidney International*, Vol.13, No.6, (June 1978), pp. 492-504, ISSN 0085-2538
- Thomson, N.M.; Holdsworth, S.R., Glasgow, E.F. & Atkins, R.C. (1979). The macrophage in the development of experimental crescentic glomerulonephritis. Studies using tissue culture and electron microscopy. *The American Journal of Pathology*, Vol.94, No.2, (February 1979), pp. 223-240, ISSN 0002-9440
- Timoshanko, J.R.; Holdsworth, S.R., Kitching, A.R. & Tipping, P.G. (2002). IFN-gamma production by intrinsic renal cells and bone marrow-derived cells is required for full expression of crescentic glomerulonephritis in mice. *Journal of Immunology*, Vol.168, No.8, (April 2002), pp. 4135-4141, ISSN 0022-1767

- Tipping, P.G.; Lowe, M.G. & Holdsworth, S.R. (1988). Glomerular macrophages express augmented procoagulant activity in experimental fibrin-related glomerulonephritis in rabbits. *The Journal of Clinical Investigation*, Vol.82, No.4, (October 1988), pp. 1253–1259, ISSN 0021-9738
- Vanacore, R.M.; Ham, A.J., Cartailier, J.P., Sundaramoorthy, M., Todd, P., Pedchenko, V., Sado, Y., Borza, D.B. & Hudson, B.G. (2008). A role for collagen IV cross-links in conferring immune privilege to the Goodpasture autoantigen: structural basis for the crypticity of B cell epitopes. *The Journal of Biological Chemistry*, Vol.283, No.33, (August 2008), pp. 22737–22748, ISSN 0021-9258
- Vanacore, R.M.; Ham, A.J., Voehler, M., Sanders, C.R., Conrads, T.P., Veenstra, T.D., Sharpless, K.B., Dawson, P.E. & Hudson, B.G. (2009). A sulfilimine bond identified in collagen IV. *Science*, Vol.325, No.5945, (September 2009), pp. 1230–1234, ISSN 0036-8075
- Walker, R.G.; Scheinkestel, C., Becker, G.J., Owen, J.E., Dowling, J.P. & Kincaid-Smith, P. (1985). Clinical and morphological aspects of the management of crescentic anti-glomerular basement membrane antibody (anti-GBM) nephritis/Goodpasture's syndrome. *The Quarterly Journal of Medicine*, Vol.54, No.213, (January 1985), pp. 75–89, ISSN 0033-5622
- Williams, P.S.; Davenport, A., McDicken, I., Ashby, D., Goldsmith, H.J. & Bone, J.M. (1988). Increased incidence of anti-glomerular basement membrane antibody (anti-GBM) nephritis in the Mersey Region, September 1984–October 1985. *The Quarterly Journal of Medicine*, Vol.68, No.257, (September 1988), pp. 727–733, ISSN 0033-5622
- Wilson, C.B. & Dixon, F.J. (1973). Anti-glomerular basement membrane antibody-induced glomerulonephritis. *Kidney International*, Vol.3, No.2, (February 1973), pp. 74–89, ISSN 0085-2538
- Yang, G.; Tang, Z., Chen, Y., Zeng, C., Chen, H., Liu, Z. & Li, L. (2005). Antineutrophil cytoplasmic antibodies (ANCA) in Chinese patients with anti-GBM crescentic glomerulonephritis. *Clinical Nephrology*, Vol.63, No.6, (June 2005), pp. 423–428, ISSN 0301-0430
- Yang, R.; Cui, Z., Zhao, J. & Zhao, M.H. (2009). The role of HLA-DRB1 alleles on susceptibility of Chinese patients with anti-GBM disease. *Clinical Immunology*, Vol.133, No.2, (November 2009), pp. 245–250, ISSN 1521-6616
- Zhou, X.J.; Lv, J.C., Yu, L., Cui, Z., Zhao, J., Yang, R., Han, J., Hou, P., Zhao, M.H. & Zhang, H. (2010a). FCGR2b gene polymorphism rather than FCGR2A, FCGR3A and FCGR3B is associated with anti-GBM disease in Chinese. *Nephrology Dialysis Transplantation*, Vol.25, No.1, (January 2010), pp. 97–101, ISSN 0931-0509
- Zhou, X.J.; Lv, J.C., Bu, D.F., Yu, L., Yang, Y.R., Zhao, J., Cui, Z., Yang, R., Zhao, M.H. & Zhang, H. (2010b). Copy number variation of FCGR3A rather than FCGR3B and FCGR2B is associated with susceptibility to anti-GBM disease. *International Immunology*, Vol.22, No.1, (January 2010), pp. 45–51, ISSN 1460-2377
- Hirayama, K.; Yamagata, K., Kobayashi, M., Koyama, A. (2008). Anti-glomerular basement membrane antibody disease in Japan: part of the nationwide rapidly progressive glomerulonephritis survey in Japan. *Clinical and Experimental Nephrology*, Vol.12, No.5, (October 2008), pp. 339–347, ISSN 1342-1751

An Update on Glomerulopathies - Clinical and Treatment Aspects

Edited by Prof. Sharma Prabhakar

ISBN 978-953-307-673-7

Hard cover, 468 pages

Publisher InTech

Published online 02, November, 2011

Published in print edition November, 2011

An Update on Glomerulopathies - Clinical and Treatment Aspects is a systemic overview of recent advances in clinical aspects and therapeutic options in major syndromes of glomerular pathology. The book contains twenty four chapters divided conveniently into five sections. The first section deals with primary glomerulopathies, and the second section is devoted to glomerulopathies complicating infectious conditions. The third section deals with systemic autoimmune disorders and vasculitides which constitute major causes of glomerular disease and often renal failure. The fourth section includes chapters discussing the glomerular involvement in some major metabolic and systemic conditions. The final section has chapters which relate to some general aspects of glomerular diseases. This book will form an excellent reference tool for practicing and academic nephrology community.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Kouichi Hirayama and Kunihiro Yamagata (2011). Anti-Glomerular Basement Membrane Disease, An Update on Glomerulopathies - Clinical and Treatment Aspects, Prof. Sharma Prabhakar (Ed.), ISBN: 978-953-307-673-7, InTech, Available from: <http://www.intechopen.com/books/an-update-on-glomerulopathies-clinical-and-treatment-aspects/anti-glomerular-basement-membrane-disease>

INTech
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2011 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](https://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen